Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss

Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q1 EPS of ($2.43), $1.52 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $5.9 million.

For earnings history and earnings-related data on Opiant Pharmaceuticals (OPNT) click here.

You May Also Be Interested In

• Parsons Corporation (PSN) Tops Q2 EPS by 10c; Offers Guidance
• L’Oréal posts 6.8% H1 sales growth, record margins
• Trip.com Group Limited (TCOM) PT Lowered to $60 at BofA Securities